fb_script

Immunotherapy found to be safe in pilot study of people with T1D

A pilot clinical trial in the US has found a new immunotherapy treatment to be safe in people with new onset type 1 diabetes (T1D).

After clinical presentation of T1D, beta cell loss continues progressively in most people until C-peptide levels, a marker of endogenous insulin production, is absent or present in very low levels. Despite intensive research efforts for more than 20 years, no therapy is currently available to prevent beta cell loss in T1D.

Read More

Innovative biodegradable scaffold protects transplanted islets

A new technique that could drastically improve outcomes of human islet transplantation has been successful in a world-first clinical trial.

BioHub scaffold

The technique, developed by the US-based Diabetes Research Institute (DRI) and supported in part by JDRF funding, involves transplanting islets in a biodegradable ‘scaffold’ into the omentum, a fold of tissue that covers and protects the abdominal organs. Read More